BREAST CANCER DETECTION KIT USING SALIVA AND BREAST CANCER DETECTION METHOD USING SAME, AND FERTILE WINDOW DETECTION KIT USING SALIVA AND FERTILE WINDOW DETECTION METHOD USING SAME

Abstract

A breast cancer detection kit using saliva and a breast cancer detection method using the kit, which are presented in the present invention, can detect breast cancer more accurately than a conventional breast cancer detection technique. In addition, a fertile window detection kit using saliva and a fertile window detection method using the kit, which are presented in the present invention, can resolve inconveniences of limitations on time and place in a conventional technology for confirming whether there is a fertile window through urine, and can solve problems, of a conventional technique for determining the structure of saliva through observation, in which saliva takes a certain amount of time to dry and the observation, itself, of spit can arouse visual discomfort, in order to confirm the salt crystals of saliva or the structural shape of saliva.

Claims

1. A breast cancer detection kit using saliva, the breast cancer detection kit comprising: a collection module configured to collect saliva of a user; a detection module configured to detect a breast cancer marker from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the breast cancer marker from the saliva collected from the collection module; an analysis module configured to analyze a presence of breast cancer by using an immune reaction of the breast cancer marker detected from the detection module; and a display module configured to display information to confirm the presence of breast cancer based on the analysis result of the analysis module.

2. The breast cancer detection kit of claim 1, wherein the breast cancer marker comprises at least one of Lysine (409.2312 m/z), Threonine (131.1174 m/z), Glutamic acid, Tyrosine, Piperideine, Valine, and Glycine (437.7442 m/z).

3. The breast cancer detection kit of claim 1, wherein the mucus glycoproteins comprise mucosal glycoproteins.

4. The breast cancer detection kit of claim 1, wherein the removal of the mucus glycoproteins is obtained by decomposing glucoproteins within the collected saliva.

5. The breast cancer detection kit of claim 4, wherein mucus is removed to purify the saliva after decomposing the glucoproteins.

6. The breast cancer detection kit of claim 1, wherein the detection module is configured to remove microorganisms from the collected saliva.

7. The breast cancer detection kit of claim 1, wherein the detection module is configured to change a pH value of the collected saliva into pH7.

8. The breast cancer detection kit of claim 1, wherein the detection module is configured to add a buffer solution to mix the buffer solution with the collected saliva.

9. The breast cancer detection kit of claim 1, wherein the analysis module is configured to analyze the presence of breast cancer through an antigen-antibody reaction, in which an immune reaction of the analysis module is the antigen-antibody reaction between the breast cancer marker detected from the collected saliva and an antibody.

10. The breast cancer detection kit of claim 9, wherein the breast cancer marker sequentially reacts with the antibody, promotes a color formation, and amplifies the promoted color formation.

11. A breast cancer detection method using a breast cancer detection kit using saliva, the breast cancer detection method comprising: (a) collecting, by a collection module, saliva of a user; (b) detecting, by a detection module, a breast cancer marker from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the breast cancer marker from the saliva collected from the collection module of step (a); (c) analyzing, by an analysis module, a presence of breast cancer by using an immune reaction of the breast cancer marker detected from the detection module of step (b); and (d) displaying, by a display module, information to confirm the presence of breast cancer based on the analysis result of the analysis module of step (c).

12. The breast cancer detection method of claim 11, wherein the breast cancer marker comprises at least one of Lysine (409.2312 m/z), Threonine (131.1174 m/z), Glutamic acid, Tyrosine, Piperideine, Valine, and Glycine (437.7442 m/z).

13. The breast cancer detection method of claim 11, wherein the mucus glycoproteins comprise mucosal glycoproteins.

14. The breast cancer detection method of claim 11, wherein the removal of the mucus glycoproteins is obtained by decomposing glucoproteins within the collected saliva.

15. The breast cancer detection method of claim 14, wherein mucus is removed to purify the saliva after decomposing the glucoproteins.

16. The breast cancer detection method of claim 11, wherein the detection module is configured to remove microorganisms from the collected saliva.

17. The breast cancer detection method of claim 11, wherein the detection module is configured to change a pH value of the collected saliva into pH7.

18. The breast cancer detection method of claim 11, wherein the detection module is configured to add a buffer solution to mix the buffer solution with the collected saliva.

19. The breast cancer detection method of claim 11, wherein the analysis module is configured to analyze the presence of breast cancer through an antigen-antibody reaction, in which an immune reaction of the analysis module is the antigen-antibody reaction between the breast cancer marker detected from the collected saliva and an antibody.

20. The breast cancer detection method of claim 19, wherein the breast cancer marker sequentially reacts with the antibody, promotes a color formation, and amplifies the promoted color formation.

21. A fertile window detection kit using saliva, the fertile window detection kit comprising: a collection module configured to collect saliva of a user; a detection module configured to detect a hormone from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the hormone from the saliva collected from the collection module; an analysis module configured to analyze whether there is a fertile window by using an immune reaction of the hormone detected from the detection module; and a display module configured to display information to confirm whether there is a fertile window based on the analysis result of the analysis module.

22. The fertile window detection kit of claim 21, wherein the hormone comprises a luteinizing hormone.

23. The fertile window detection kit of claim 21, wherein the mucus glycoproteins comprise mucosal glycoproteins.

24. The fertile window detection kit of claim 21, wherein the removal of the mucus glycoproteins is obtained by decomposing glucoproteins within the collected saliva.

25. The fertile window detection kit of claim 24, wherein mucus is removed to purify the saliva after decomposing the glucoproteins.

26. The fertile window detection kit of claim 21, wherein the detection module is configured to remove microorganisms from the collected saliva.

27. The fertile window detection kit of claim 21, wherein the detection module is configured to change a pH value of the collected saliva into pH7.

28. The fertile window detection kit of claim 21, wherein the detection module is configured to add a buffer solution to mix the buffer solution with the collected saliva.

29. The fertile window detection kit of claim 21, wherein the analysis module is configured to analyze whether there is a fertile window through an antigen-antibody reaction, in which an immune reaction of the analysis module is the antigen-antibody reaction between the hormone detected from the collected saliva and an antibody.

30. The fertile window detection kit of claim 29, wherein the hormone sequentially reacts with the antibody, promotes a color formation, and amplifies the promoted color formation.

31. A fertile window detection method using a fertile window detection kit using saliva, the fertile window detection method comprising: (a) collecting, by a collection module, saliva of a user; (b) detecting, by a detection module, a hormone from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the hormone from the saliva collected from the collection module of step (a); (c) analyzing, by an analysis module, whether there is a fertile window by using an immune reaction of the hormone detected from the detection module of step (b); and (d) displaying, by a display module, information to confirm whether there is a fertile window based on the analysis result of the analysis module of step (c).

32. The fertile window detection method of claim 31, wherein the hormone comprises a luteinizing hormone.

33. The fertile window detection method of claim 31, wherein the mucus glycoproteins comprise mucosal glycoproteins.

34. The fertile window detection method of claim 31, wherein the removal of the mucus glycoproteins is obtained by decomposing glucoproteins within the collected saliva.

35. The fertile window detection method of claim 34, wherein mucus is removed to purify the saliva after decomposing the glucoproteins.

36. The fertile window detection method of claim 31, wherein the detection module is configured to remove microorganisms from the collected saliva.

37. The fertile window detection method of claim 31, wherein the detection module is configured to change a pH value of the collected saliva into pH7.

38. The fertile window detection method of claim 31, wherein the detection module is configured to add a buffer solution to mix the buffer solution with the collected saliva.

39. The fertile window detection method of claim 31, wherein the analysis module is configured to analyze whether there is a fertile window through an antigen-antibody reaction, in which an immune reaction of the analysis module is the antigen-antibody reaction between the hormone detected from the collected saliva and an antibody.

40. The fertile window detection method of claim 39, wherein the hormone sequentially reacts with the antibody, promotes a color formation, and amplifies the promoted color formation.

Description

DESCRIPTION OF THE DRAWINGS

[0058] FIG. 1 is a view showing a test result of a conventional mammography.

[0059] FIG. 2 is a view showing a test result of a conventional breast ultrasonography.

[0060] FIG. 3 is a view for explaining a woman's menstrual cycle.

[0061] FIG. 4 is a view showing a conventional ovulation tester using urine.

[0062] FIG. 5 is a view showing a conventional portable ovulation tester using saliva.

[0063] FIG. 6 is a view for explaining a detection principle of a conventional portable ovulation tester using saliva.

[0064] FIG. 7 is a view showing an entire configuration of a breast cancer detection kit using saliva according to one embodiment of the present invention.

[0065] FIG. 8 is a view for explaining a general antigen-antibody reaction.

[0066] FIG. 9 is a view for explaining a color formation reaction through a general antigen-antibody reaction.

[0067] FIG. 10 is a flowchart showing a breast cancer detection method using a breast cancer detection kit using saliva according to one embodiment of the present invention.

[0068] FIG. 11 is a view showing an entire configuration of a fertile window detection kit using saliva according to one embodiment of the present invention.

[0069] FIG. 12 is a flowchart showing a fertile window detection method using a fertile window detection kit using saliva according to one embodiment of the present invention.

DESCRIPTION OF REFERENCE NUMERALS

[0070] 10: Breast cancer detection kit using saliva according to one embodiment of the present invention [0071] 10: Fertile window detection kit using saliva according to one embodiment of the present invention [0072] 100, 100: Collection module [0073] 200, 200: Detection module [0074] 300, 300: Analysis module [0075] 400, 400: Display module

BEST MODE

[0076] Hereinafter, the preferred embodiments will be described in detail such that those skilled in the art to which the present invention pertains may easily carry out the present invention with reference to the accompanying drawings. In the following description of the present invention, a detailed description of known functions and configurations incorporated herein will be omitted when it may make the subject matter of the present invention unnecessarily unclear.

[0077] In addition, when a part is referred to as being connected to another part, it includes not only directly connected, but also indirectly connected with another element interposed therebetween throughout the specification. In addition, when a component is referred to as including a certain element, it is to be understood that the component may further include other elements as well without excluding the other elements unless specifically defined otherwise.

[0078] FIG. 7 is a view showing an entire configuration of a breast cancer detection kit using saliva according to one embodiment of the present invention. As shown in FIG. 7, the breast cancer detection kit 10 using saliva according to one embodiment of the present invention is configured to include: a collection module 100 configured to collect saliva of a user; a detection module 200 configured to detect a breast cancer marker from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the breast cancer marker from the saliva collected from the collection module 100; an analysis module 300 configured to analyze a presence of breast cancer by using an immune reaction of the breast cancer marker detected from the detection module 200; and a display module 400 configured to display information to confirm the presence of breast cancer based on the analysis result of the analysis module 300.

[0079] The collection module 100 plays a role to collect saliva from a user, and the detection module 200 plays a role to detect a breast cancer marker from the saliva collected from the collection module 100. The breast cancer marker collected may include at least one of Lysine (409.2312 m/z), Threonine (131.1174 m/z), Glutamic acid, Tyrosine, Piperideine, Valine, and Glycine (437.7442 m/z).

[0080] The detection module 200 may be configured to remove mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the breast cancer marker, and the mucus glycoproteins may include mucosal glycoproteins. Specifically, the detection module may be configured to sequentially decompose glycoproteins by using a syringe filter, remove mucus, and remove mucus glycoproteins to purify saliva, in order to measure the proteins contained in the saliva. The detection module may be configured to remove microorganisms from the collected saliva after removing mucus glycoproteins therefrom. Further, the detection module 200 may be configured to change a pH value of the collective saliva from pH5-6 into pH7. Such change aims at creating an environment in which an immune reaction to be described below, that is, an antigen-antibody reaction may be smoothly performed. According to embodiments, a buffer solution may be added to mix with the collected saliva, thereby facilitating the immune reaction.

[0081] The analysis module 300 plays a role to analyze a presence of breast cancer by using an immune reaction of the breast cancer marker detected from the detection module 200. FIG. 8 is a view for explaining a general antigen-antibody reaction. It may be confirmed that a shape of a capture antibody, a shape of the reaction between the antibody and a target antigen, a shape of the reaction with an antibody conjugated with horseradish peroxidase (HRP), and a shape of the color formation with the antibody conjugated with HRP by using TMB are shown in order from the left. In the breast cancer detection kit 10 using saliva according to the present invention, an immune reaction of the analysis module 300 is an antigen-antibody reaction between the breast cancer marker detected from the collected saliva and the antibody as shown in the reaction of FIG. 8, in which a presence of breast cancer may be analyzed through such antigen-antibody reaction. According to embodiments, the detection module 200 may be configured in such a way that the purified saliva passes through a sheet and a breast cancer marker having passed through the sheet reacts with an antibody to promote a color formation as a result of the reaction and amplify the promoted color formation.

[0082] FIG. 9 is a view for explaining a color formation reaction through a general antigen-antibody reaction, in which test results are confirmed by using an antigen-antibody color formation reaction. With regard to the color formation reaction, there is a difference between pregnancy or ovulation and HIV or hepatitis C. In case of pregnancy or ovulation, an antigen hCG or LH in urine, an antibody conjugated with gold grains, and an antibody in a result line are subjected to a double reaction to show a color formation reaction. In contrast, in case of HIV or hepatitis C, an antibody produced in body against an invading exogenous antigen and an antigen in a result line are subjected to a reaction to show a color formation reaction and confirm the result. The breast cancer detection kit 10 using saliva according to the present invention is also configured to carry out a color formation through the color formation reaction of the antibody as described in FIG. 9, and promote and amplify such color formation.

[0083] The display module 400 plays a role to display information such that a user may confirm the presence of breast cancer based on the analysis result of the analysis module 300. In other words, the analysis module 300 is configured to analyze the presence of breast cancer from the results of color formation, promotion and amplification through an immune reaction. The display module 400 is configured to display information such that a user may recognize whether the analysis result of the analysis module 300 shows the breast cancer or not. Each of the collection module 100, the detection module 200, the analysis module 300 and the display module 400 may be configured in a separate way, but preferably may be all disposed in one kit. In this case, the kit has an advantage of being small-sized, more portable and thus having more popularity in use.

[0084] FIG. 10 is a flowchart showing a breast cancer detection method using a breast cancer detection kit using saliva according to one embodiment of the present invention. As shown in FIG. 10, the breast cancer detection method using a breast cancer detection kit 10 using saliva according to one embodiment of the present invention is configured to include: collecting, by a collection module 100, saliva of a user (S100); detecting, by a detection module 200, a breast cancer marker from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the breast cancer marker from the saliva collected from the collection module of step S100 (S200); analyzing, by an analysis module 300, a presence of breast cancer by using an immune reaction of the breast cancer marker detected from the detection module 200 of step S200 (S300); and displaying, by a display module 400, information to confirm the presence of breast cancer based on the analysis result of the analysis module 300 of step S300 (S400).

[0085] The details of each of the steps have been fully described above with regard to the breast cancer detection kit 10 using saliva according to one embodiment of the present invention, and thus the detailed description thereof will be omitted below.

[0086] Meanwhile, FIG. 11 is a view showing an entire configuration of a fertile window detection kit using saliva according to one embodiment of the present invention. As shown in FIG. 11, the fertile window detection kit 10 using saliva according to one embodiment of the present invention is configured to include: a collection module 100 configured to collect saliva of a user; a detection module 200 configured to detect a hormone from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the hormone from the saliva collected from the collection module 100; an analysis module 300 configured to analyze whether there is a fertile window by using an immune reaction of the hormone detected from the detection module 200; and a display module 400 configured to display information to confirm whether there is a fertile window based on the analysis result of the analysis module 300.

[0087] The collection module 100 plays a role to collect saliva from a user, and the detection module 200 plays a role to detect a hormone from the saliva collected from the collection module 100. The collected hormone may include a luteinizing hormone.

[0088] The detection module 200 may be configured to remove mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the hormone, and the mucus glycoproteins may include mucosal glycoproteins. Specifically, the detection module may be configured to sequentially decompose glycoproteins by using a syringe filter, remove mucus, and remove mucus glycoproteins to purify saliva, in order to measure the proteins contained in the saliva. The detection module may be configured to remove microorganisms from the collected saliva after removing mucus glycoproteins therefrom. Further, the detection module 200 may be configured to change a pH value of the collective saliva from pH5-6 into pH7. Such change aims at creating an environment in which an immune reaction to be described below, that is, an antigen-antibody reaction may be smoothly performed. According to embodiments, a buffer solution may be added to mix with the collected saliva, thereby facilitating the immune reaction.

[0089] The analysis module 300 plays a role to analyze whether there is a fertile window by using an immune reaction of the hormone detected from the detection module 200. As described above, FIG. 8 is a view for explaining a general antigen-antibody reaction. It may be confirmed that a shape of a capture antibody, a shape of the reaction between the antibody and a target antigen, a shape of the reaction with an antibody conjugated with horseradish peroxidase (HRP), and a shape of the color formation with the antibody conjugated with HRP by using TMB are shown in order from the left. In the fertile window detection kit 10 using saliva according to the present invention, an immune reaction of the analysis module 300 is an antigen-antibody reaction between the hormone detected from the collected saliva and the antibody as shown in the reaction of FIG. 8, in which whether there is a fertile window may be analyzed through such antigen-antibody reaction. According to embodiments, the detection module 200 may be configured in such a way that the purified saliva passes through a sheet and a hormone having passed through the sheet reacts with an antibody to promote a color formation as a result of the reaction and amplify the promoted color formation.

[0090] As described above, FIG. 9 is a view for explaining a color formation reaction through a general antigen-antibody reaction, in which test results are confirmed by using an antigen-antibody color formation reaction. With regard to the color formation reaction, there is a difference between pregnancy or ovulation and HIV or hepatitis C. In case of pregnancy or ovulation, an antigen hCG or LH in urine, an antibody conjugated with gold grains, and an antibody in a result line are subjected to a double reaction to show a color formation reaction. In contrast, in case of HIV or hepatitis C, an antibody produced in body against an invading exogenous antigen and an antigen in a result line are subjected to a reaction to show a color formation reaction and confirm the result. The fertile window detection kit 10 using saliva according to the present invention is also configured to carry out a color formation through the color formation reaction of the antibody as described in FIG. 9, and promote and amplify such color formation.

[0091] The display module 400 plays a role to display information such that a user may confirm whether there is a fertile window based on the analysis result of the analysis module 300. In other words, the analysis module 300 is configured to analyze whether there is a fertile window from the results of color formation, promotion and amplification through an immune reaction. The display module 400 is configured to display information such that a user may recognize whether there is a fertile window based on the analysis result of the analysis module 300. Each of the collection module 100, the detection module 200, the analysis module 300 and the display module 400 may be configured in a separate way, but preferably may be all disposed in one kit. In this case, the kit has an advantage of being small-sized, more portable and thus having more popularity in use.

[0092] FIG. 12 is a flowchart showing a fertile window detection method using a fertile window detection kit using saliva according to one embodiment of the present invention. As shown in FIG. 12, the fertile window detection method using a fertile window detection kit 10 using saliva according to one embodiment of the present invention is configured to include: collecting, by a collection module 100, saliva of a user (S100); detecting, by a detection module 200, a hormone from the saliva after removing mucus glycoproteins from the collected saliva as a pre-treatment process for detecting the hormone from the saliva collected from the collection module of step S100 (S200); analyzing, by an analysis module 300, whether there is a fertile window by using an immune reaction of the hormone detected from the detection module 200 of step S200 (S300); and displaying, by a display module 400, information to confirm whether there is a fertile window based on the analysis result of the analysis module 300 of step S300 (S400).

[0093] The details of each of the steps have been fully described above with regard to the fertile window detection kit 10 using saliva according to one embodiment of the present invention, and thus the detailed description thereof will be omitted below.

[0094] The present invention as described above may be subjected to various modifications or applications by those skilled in the art to which the present invention pertains, and the technical scope of the present invention may be determined by the patent claims to be described below.